» Articles » PMID: 9859996

Identification of the Receptor Component of the IkappaBalpha-ubiquitin Ligase

Overview
Journal Nature
Specialty Science
Date 1998 Dec 22
PMID 9859996
Citations 229
Authors
Affiliations
Soon will be listed here.
Abstract

NF-kappaB, a ubiquitous, inducible transcription factor involved in immune, inflammatory, stress and developmental processes, is retained in a latent form in the cytoplasm of non-stimulated cells by inhibitory molecules, IkappaBs. Its activation is a paradigm for a signal-transduction cascade that integrates an inducible kinase and the ubiquitin-proteasome system to eliminate inhibitory regulators. Here we isolate the pIkappaBalpha-ubiquitin ligase (pIkappaBalpha-E3) that attaches ubiquitin, a small protein which marks other proteins for degradation by the proteasome system, to the phosphorylated NF-kappaB inhibitor pIkappaBalpha. Taking advantage of its high affinity to pIkappaBalpha, we isolate this ligase from HeLa cells by single-step immunoaffinity purification. Using nanoelectrospray mass spectrometry, we identify the specific component of the ligase that recognizes the pIkappaBalpha degradation motif as an F-box/WD-domain protein belonging to a recently distinguished family of beta-TrCP/Slimb proteins. This component, which we denote E3RSIkappaB (pIkappaBalpha-E3 receptor subunit), binds specifically to pIkappaBalpha and promotes its in vitro ubiquitination in the presence of two other ubiquitin-system enzymes, E1 and UBC5C, one of many known E2 enzymes. An F-box-deletion mutant of E3RS(IkappaB), which tightly binds pIkappaBalpha but does not support its ubiquitination, acts in vivo as a dominant-negative molecule, inhibiting the degradation of pIkappaBalpha and consequently NF-kappaB activation. E3RS(IkappaB) represents a family of receptor proteins that are core components of a class of ubiquitin ligases. When these receptor components recognize their specific ligand, which is a conserved, phosphorylation-based sequence motif, they target regulatory proteins containing this motif for proteasomal degradation.

Citing Articles

Macrocyclic peptides as a new class of targeted protein degraders.

Jing X, Mackay J, Passioura T RSC Chem Biol. 2025; 6(3):326-337.

PMID: 39822773 PMC: 11733494. DOI: 10.1039/d4cb00199k.


Exploring TNFR1: from discovery to targeted therapy development.

Li Y, Ye R, Dai H, Lin J, Cheng Y, Zhou Y J Transl Med. 2025; 23(1):71.

PMID: 39815286 PMC: 11734553. DOI: 10.1186/s12967-025-06122-0.


PROTAR Vaccine 2.0 generates influenza vaccines by degrading multiple viral proteins.

Zhang C, Hou J, Li Z, Shen Q, Bai H, Chen L Nat Chem Biol. 2025; .

PMID: 39814992 DOI: 10.1038/s41589-024-01813-z.


Bimetallic clusterzymes-loaded dendritic mesoporous silica particle regulate arthritis microenvironment ROS scavenging and YAP1 stabilization.

Jin Y, Hu C, Xia J, Xie D, Ye L, Ye X Bioact Mater. 2024; 42:613-627.

PMID: 39314862 PMC: 11417149. DOI: 10.1016/j.bioactmat.2024.09.004.


TAK1 in Vascular Signaling: "Friend or Foe"?.

Fan G, Lu J, Zha J, Guo W, Zhang Y, Liu Y J Inflamm Res. 2024; 17:3031-3041.

PMID: 38770174 PMC: 11104388. DOI: 10.2147/JIR.S458948.